Muutke küpsiste eelistusi

E-raamat: Engineering Health: How Biotechnology Changed Medicine

Edited by (Visiting fellow, University College London, UK and Managing editor WhatIsBiotechnology.org)
  • Formaat: EPUB+DRM
  • Ilmumisaeg: 25-Oct-2017
  • Kirjastus: Royal Society of Chemistry
  • Keel: eng
  • ISBN-13: 9781788012348
Teised raamatud teemal:
  • Formaat - EPUB+DRM
  • Hind: 29,63 €*
  • * hind on lõplik, st. muud allahindlused enam ei rakendu
  • Lisa ostukorvi
  • Lisa soovinimekirja
  • See e-raamat on mõeldud ainult isiklikuks kasutamiseks. E-raamatuid ei saa tagastada.
  • Formaat: EPUB+DRM
  • Ilmumisaeg: 25-Oct-2017
  • Kirjastus: Royal Society of Chemistry
  • Keel: eng
  • ISBN-13: 9781788012348
Teised raamatud teemal:

DRM piirangud

  • Kopeerimine (copy/paste):

    ei ole lubatud

  • Printimine:

    ei ole lubatud

  • Kasutamine:

    Digitaalõiguste kaitse (DRM)
    Kirjastus on väljastanud selle e-raamatu krüpteeritud kujul, mis tähendab, et selle lugemiseks peate installeerima spetsiaalse tarkvara. Samuti peate looma endale  Adobe ID Rohkem infot siin. E-raamatut saab lugeda 1 kasutaja ning alla laadida kuni 6'de seadmesse (kõik autoriseeritud sama Adobe ID-ga).

    Vajalik tarkvara
    Mobiilsetes seadmetes (telefon või tahvelarvuti) lugemiseks peate installeerima selle tasuta rakenduse: PocketBook Reader (iOS / Android)

    PC või Mac seadmes lugemiseks peate installima Adobe Digital Editionsi (Seeon tasuta rakendus spetsiaalselt e-raamatute lugemiseks. Seda ei tohi segamini ajada Adober Reader'iga, mis tõenäoliselt on juba teie arvutisse installeeritud )

    Seda e-raamatut ei saa lugeda Amazon Kindle's. 

In an accessible style, this book examines how biotechnology tools came to be discovered, how they are being used in medicine, and what the future of medicine could look like.



Biotechnology harnesses cellular and biochemical systems to advance knowledge of the molecular cause of disease and to provide new diagnostic tools and more precisely targeted drugs. Within a decade, global investment in medical biotechnology has increased more than ten-fold, resulting in therapies for previously untreatable conditions. But what exactly is biotechnology and what are its origins? What further benefits to human health could it offer in the future?
Written in an accessible style, contributors to this book explore the history behind different biotechnology tools, how they are used, and how they are reshaping the future of diagnostics, therapeutics and vaccines. Among the technologies examined are genetic engineering, DNA sequencing, monoclonal antibodies, stem cells, gene therapy, cancer immunotherapy and the most recent newcomer - synthetic biology.
Applying new biotechnologies in medicine is not without great challenges. As medicines shift from small organic molecules to large, complex structures, such as therapeutic proteins, drugs become difficult to make, administer and regulate. This book will intrigue anyone interested in medicine and how we have been, and may continue to, engineer better health for ourselves. Such changes have major implications for how and where drugs are manufactured, the cost of medicine and the ethics of how far society is prepared to go to combat disease.

Arvustused

The book has turned out surprisingly readable, with Marks own chapters being very accessible and lay-friendly. The book impresses with 19th and 20th century historical connections to things that are topical today. * Chemistry & Industry Magazine, Issue 05, 2018 *

Chapter 1 Introduction: Biotechnology---An Ever Expanding Toolbox for Medicine
1(26)
Lara V. Marks
1.1 Introduction
1(1)
1.2 Molecular Disease and DNA
2(3)
1.3 Genetic Engineering and Its Controversial Beginning
5(3)
1.4 Monoclonal Antibodies
8(1)
1.5 DNA Sequencing
9(3)
1.6 Whole Genome Sequencing---A Weapon Against Antimicrobial Resistance
12(1)
1.7 CRISPR: A New Gene Editing Tool and Controversy
13(2)
1.8 Transgenic Animals
15(1)
1.9 Gene Therapy
16(2)
1.10 Stem Cells
18(1)
1.11 Impact in the Clinic---Eye Disease
18(1)
1.12 Cellular Therapy: A New Disruptive Technology
19(1)
1.13 Cost Implications
20(1)
1.14 Synthetic Biology
21(1)
1.15 Conclusion
22(5)
References
23(4)
Chapter 2 Biopharmaceutical Proteins: The Manufacturing Challenge
27(27)
Richard Alldread
John Birch
2.1 Introduction
27(1)
2.2 The Emergence of a New Technology
28(10)
2.2.1 Other Host Organisms for Production
32(1)
2.2.2 Mammalian Cell Culture
32(4)
2.2.3 Alternative Production Systems
36(1)
2.2.4 Generating Cells for the Production Process
37(1)
2.3 Monoclonal Antibody Technology
38(3)
2.4 Manufacturing Challenges: Process Technology
41(5)
2.4.1 Growing Cells to Make Enough Product
42(1)
2.4.2 Making the Right Product
43(1)
2.4.3 Recovering the Product
44(1)
2.4.4 Product Purification
44(1)
2.4.5 Enhancing the Product's Medicinal Effect
45(1)
2.4.6 Preparing the Final Product
46(1)
2.5 An Evolving Industry
46(5)
2.5.1 Economic Factors---Cost of Goods
47(1)
2.5.2 Geographic Factors---A Global Industry
47(1)
2.5.3 Scientific Factors---New Products and Stratified Medicine
47(1)
2.5.4 Choice of Organisms for Future Production
48(1)
2.5.5 Future Manufacturing Plants
49(1)
2.5.6 Process Analytical and Control Technology
50(1)
2.6 Conclusion
51(3)
References
51(3)
Chapter 3 Vaccines: The Recombinant Revolution
54(18)
Barry C. Buckland
3.1 Legacy Vaccines
54(1)
3.2 Hepatitis B Vaccine
55(6)
3.3 HPV Vaccine
61(5)
3.4 Influenza Vaccine (Flublok)
66(2)
3.5 Conclusion
68(4)
References
69(3)
Chapter 4 Monoclonal Antibodies: A Revolution in the Transformation of Healthcare
72(25)
Lara V. Marks
4.1 Introduction
72(1)
4.2 What is a Monoclonal Antibody
73(1)
4.3 Understanding the Nature of Immunity
73(2)
4.4 Sourcing Antibodies---The Road to Monoclonal Antibodies
75(1)
4.5 A Revolutionary Tool for Medical Laboratory Research
76(1)
4.6 A New Tool for Diagnostics
77(1)
4.7 The Road to Therapeutics
78(1)
4.8 A Hesitant Start in Therapeutics
79(1)
4.9 Engineering Human Monoclonal Antibodies
80(5)
4.9.1 Humanising Murine Antibodies
82(1)
4.9.2 Fully Human Antibodies
82(3)
4.10 The Changing Composition of Mabs
85(1)
4.11 Disease Conditions
86(3)
4.11.1 Auto-immune Disorders
88(1)
4.11.2 Cancer
88(1)
4.11.3 Other Conditions
89(1)
4.12 The Success of Mabs
89(1)
4.13 The Cost Dilemma
90(2)
4.14 Conclusion
92(5)
References
93(4)
Chapter 5 The Changing Fortune of Cancer Immunotherapy
97(29)
Lara V. Marks
5.1 Introduction
97(1)
5.2 Early Cancer Vaccine Attempts
98(3)
5.3 Serum Therapy
101(1)
5.4 Shifting Attitudes to the Immune System and Cancer
102(1)
5.5 Interferon: A New Weapon Emerges
103(1)
5.6 Anti-idiotype Antibodies
104(1)
5.7 Interleukin and Adoptive Cell Therapy (ACT)
105(2)
5.8 BCG Vaccine Revived
107(2)
5.9 A New
Chapter for ACT
109(1)
5.10 Immune Checkpoint Inhibitors
110(4)
5.11 Stimulatory Checkpoint Molecules
114(1)
5.12 Conclusion: Immunotherapy Today
114(12)
References
120(6)
Chapter 6 Gene Therapy: An Evolving Story
126(21)
Courtney Addison
6.1 Introduction
126(2)
6.2 How Gene Therapy Works
128(5)
6.2.1 How Genes Cause Disease
128(2)
6.2.2 How Genes (Might) Fix Disease
130(1)
6.2.3 Technical Challenges for Gene Therapy
131(2)
6.3 The Emergence of the Gene Therapy Field
133(8)
6.3.1 The Scientific Groundwork is Laid
134(1)
6.3.2 Ethical Questions Are Raised
134(3)
6.3.3 Preparations Begin for First-in-human Gene Therapy
137(2)
6.3.4 Gene Therapy Grows Up
139(2)
6.4 Current Issues in Gene Therapy
141(2)
6.5 Conclusion
143(4)
References
144(3)
Chapter 7 Stem Cells: An Emerging Field for Medicine
147(27)
Alison Kraft
Frank Barry
7.1 Introduction
147(2)
7.2 The `Stem Cell' Concept
149(1)
7.3 Haematopoietic Stem Cells (HSCs)
149(1)
7.4 Bone Marrow Transplantation
150(2)
7.5 Stem Cell Therapy Beyond BMT
152(1)
7.6 First Wave of Commercialisation: CD34---Cell Separation and Stem Cell Enrichment
153(1)
7.7 Second Wave of Commercialisation: Regenerative Medicine
154(1)
7.8 Mesenchymal Stromal Cells (MSCs) Therapy
155(2)
7.9 Human Embryonic Stem Cells
157(2)
7.10 A Growing Field
159(1)
7.11 Umbilical Cord Banking
159(2)
7.12 Stem Cell Innovation: The Overall Landscape
161(1)
7.13 Hurdles to Commercialisation
162(1)
7.14 Third Wave of Commercialisation: The iPS Cell 2006-2016
163(4)
7.15 Conclusion
167(7)
References
169(5)
Chapter 8 Protein Therapeutics and Blinding Diseases
174(22)
Sahar Awwad
Peng T. Khaw
Steve Brocchini
8.1 Introduction
174(1)
8.2 The Eye and Blinding Disease
175(2)
8.3 Common Blinding Conditions
177(3)
8.3.1 Cataracts and Glaucoma
177(1)
8.3.2 Age-related Macular Degeneration (AMD)
177(2)
8.3.3 Diabetic Macular Edema (DME)
179(1)
8.3.4 Uveitis
179(1)
8.4 Biological Treatments
180(1)
8.5 Administering Mab Therapeutics to the Eye
180(4)
8.5.1 Challenges With Current Routes of Administration
180(1)
8.5.2 Direct Intravitreal (PVT) Injections to the Vitreous Humour
181(3)
8.6 The Changing Face of Mab Drugs
184(2)
8.7 Stem Cells
186(1)
8.8 Ciliary Neutrophic Factor
187(1)
8.9 The Challenges Behind the Clinical Development of Ophthalmic Drugs
187(4)
8.9.1 Anatomical Differences Between Human and Animal Models
187(1)
8.9.2 Overcoming Anti-drug Antibodies (ADAs) in Animals
188(1)
8.9.3 Difficulty in Stability Studies
188(1)
8.9.4 In Vitro Testing Challenges
188(3)
8.10 Cost Issues
191(1)
8.11 Conclusion
192(4)
Acknowledgements
194(1)
References
194(2)
Chapter 9 Synthetic Biology: A Game Changer?
196(20)
Paul Race
9.1 Introduction
196(1)
9.2 What's in a Name? The Origins of Synthetic Biology
197(3)
9.3 Engineering Biology and Biotechnology
200(2)
9.4 Artemisinin---Synthetic Biology Comes of Age
202(2)
9.5 Heath Economics---Reality Bites for SynBio Artemisinin
204(2)
9.6 Synthia---Synthetic Life in the Making
206(2)
9.7 Synthetic Biology Goes Mainstream---Science for the People by the People
208(2)
9.8 Ethics, Safety and Playing God
210(2)
9.9 Dare to Dream, Where Next for Synthetic Biology
212(2)
9.10 Conclusion
214(2)
References
214(2)
Chapter 10 Synthetic Biology-Engineering Tomorrow's Medicines
216(25)
Liz Fletcher
Susan Rosser
10.1 Introduction
216(1)
10.2 What Is Synthetic Biology?
217(2)
10.3 Moving on from Microbes
219(1)
10.4 Synthetic Biology for Manufacturing Medicines
220(8)
10.4.1 Better Biologics
221(1)
10.4.2 Synthetic Vaccines
222(1)
10.4.3 Engineering Cells for Drug Discovery
223(1)
10.4.4 Disease in a Dish
224(2)
10.4.5 Novel Antimicrobials
226(1)
10.4.6 Mini Organs for Better Toxicity Screening
227(1)
10.5 Synthetic Cells as Diagnostics and Theranostics
228(4)
10.5.1 Cellular Prosthesis
229(2)
10.5.2 Theranostics on the Drawing Board
231(1)
10.6 Engineering Cell Therapy
232(4)
10.6.1 Building in Controls
232(1)
10.6.2 `CAR-T Blanche' for Cancer Therapy
233(3)
10.7 Medicines and Microbes
236(2)
10.8 Conclusion
238(3)
References
238(3)
Subject Index 241